Scientific & Research Collaborations

We are your scientific partner of choice.

Collaborator	Drug Candidate	Disease
	Emavusertib (Oral Small Molecule IRAK4 Inhibitor)	Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes
	Fimepinostat	Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
	Fimepinostat	Hematologic and solid malignancies
	Fimepinostat	Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)

Investigators may request Curis to provide its compounds for clinical and non-clinical study purposes. Any information that you submit below is subject to our Privacy Policy.

Investigator-Sponsored Trial (IST) or Investigator-Initiated Trial (IIT)

Similar to clinical studies, IST or IIT studies provide qualifying patients with access to investigational drugs. Data is collected to better understand safety and efficacy where the sponsor-investigator assumes responsibility for all aspects of the research.

For IST or IIT requests by physicians click here

Material Transfer Agreement (MTA)

A request by an external entity (e.g. academic or research institution) to conduct research and/or collaborate on a Curis compound. Only compound material will be provided for this agreement.

For an MTA Request click here

Sponsor Research Agreement (SRA)

A request by an external entity (e.g. academic or research institution) to conduct research and/or collaborate on a Curis compound. This request includes funding to support the research plan.

For an SRA request click here